Defining the role of mycophenolate mofetil in the treatment of proliferative lupus nephritis

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Systemic lupus erythematosus, which predominantly affects young women, is frequently complicated by renal involvement. The presence of acute glomerulonephritis significantly adds to morbidity and mortality. Cyclophosphamide has become the mainstay of treatment in patients with proliferative forms of lupus nephritis. However, adverse events such as severe infections and infertility have spurred the search for novel treatment regimens and agents. Sequential therapy has significantly reduced adverse events. In several pilot studies, mycophenolate mofetil (MMF) has emerged as a promising therapeutic approach for both the induction and maintenance phase in patients with lupus nephritis, delivering equal efficacy and a better adverse effect profile; however, these studies had a limited power, and a large, multicentre and probably multinational clinical trial will be needed to discern the optimal therapeutic approach. On the basis of the currently available literature, sequential therapy with cyclophosphamide induction followed by azathioprine or MMF maintenance can be recommended for most patients. In selected populations, induction with MMF is a reasonable option to reduce adverse events.

Original languageEnglish
Pages (from-to)2429-2436
Number of pages8
JournalDrugs
Volume65
Issue number17
DOIs
StatePublished - Dec 6 2005

Fingerprint

Mycophenolic Acid
Lupus Nephritis
Cyclophosphamide
Azathioprine
Therapeutics
Maintenance
Glomerulonephritis
Systemic Lupus Erythematosus
Infertility
Clinical Trials
Morbidity
Kidney
Mortality
Infection
Population

ASJC Scopus subject areas

  • Toxicology
  • Health, Toxicology and Mutagenesis

Cite this

Defining the role of mycophenolate mofetil in the treatment of proliferative lupus nephritis. / Lenz, Oliver; Fornoni, Alessia; Contreras, Gabriel.

In: Drugs, Vol. 65, No. 17, 06.12.2005, p. 2429-2436.

Research output: Contribution to journalArticle

@article{5425a76991514a8dbfbe6ff2b75c827b,
title = "Defining the role of mycophenolate mofetil in the treatment of proliferative lupus nephritis",
abstract = "Systemic lupus erythematosus, which predominantly affects young women, is frequently complicated by renal involvement. The presence of acute glomerulonephritis significantly adds to morbidity and mortality. Cyclophosphamide has become the mainstay of treatment in patients with proliferative forms of lupus nephritis. However, adverse events such as severe infections and infertility have spurred the search for novel treatment regimens and agents. Sequential therapy has significantly reduced adverse events. In several pilot studies, mycophenolate mofetil (MMF) has emerged as a promising therapeutic approach for both the induction and maintenance phase in patients with lupus nephritis, delivering equal efficacy and a better adverse effect profile; however, these studies had a limited power, and a large, multicentre and probably multinational clinical trial will be needed to discern the optimal therapeutic approach. On the basis of the currently available literature, sequential therapy with cyclophosphamide induction followed by azathioprine or MMF maintenance can be recommended for most patients. In selected populations, induction with MMF is a reasonable option to reduce adverse events.",
author = "Oliver Lenz and Alessia Fornoni and Gabriel Contreras",
year = "2005",
month = "12",
day = "6",
doi = "10.2165/00003495-200565170-00001",
language = "English",
volume = "65",
pages = "2429--2436",
journal = "Drugs",
issn = "0012-6667",
publisher = "Adis International Ltd",
number = "17",

}

TY - JOUR

T1 - Defining the role of mycophenolate mofetil in the treatment of proliferative lupus nephritis

AU - Lenz, Oliver

AU - Fornoni, Alessia

AU - Contreras, Gabriel

PY - 2005/12/6

Y1 - 2005/12/6

N2 - Systemic lupus erythematosus, which predominantly affects young women, is frequently complicated by renal involvement. The presence of acute glomerulonephritis significantly adds to morbidity and mortality. Cyclophosphamide has become the mainstay of treatment in patients with proliferative forms of lupus nephritis. However, adverse events such as severe infections and infertility have spurred the search for novel treatment regimens and agents. Sequential therapy has significantly reduced adverse events. In several pilot studies, mycophenolate mofetil (MMF) has emerged as a promising therapeutic approach for both the induction and maintenance phase in patients with lupus nephritis, delivering equal efficacy and a better adverse effect profile; however, these studies had a limited power, and a large, multicentre and probably multinational clinical trial will be needed to discern the optimal therapeutic approach. On the basis of the currently available literature, sequential therapy with cyclophosphamide induction followed by azathioprine or MMF maintenance can be recommended for most patients. In selected populations, induction with MMF is a reasonable option to reduce adverse events.

AB - Systemic lupus erythematosus, which predominantly affects young women, is frequently complicated by renal involvement. The presence of acute glomerulonephritis significantly adds to morbidity and mortality. Cyclophosphamide has become the mainstay of treatment in patients with proliferative forms of lupus nephritis. However, adverse events such as severe infections and infertility have spurred the search for novel treatment regimens and agents. Sequential therapy has significantly reduced adverse events. In several pilot studies, mycophenolate mofetil (MMF) has emerged as a promising therapeutic approach for both the induction and maintenance phase in patients with lupus nephritis, delivering equal efficacy and a better adverse effect profile; however, these studies had a limited power, and a large, multicentre and probably multinational clinical trial will be needed to discern the optimal therapeutic approach. On the basis of the currently available literature, sequential therapy with cyclophosphamide induction followed by azathioprine or MMF maintenance can be recommended for most patients. In selected populations, induction with MMF is a reasonable option to reduce adverse events.

UR - http://www.scopus.com/inward/record.url?scp=28144451020&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28144451020&partnerID=8YFLogxK

U2 - 10.2165/00003495-200565170-00001

DO - 10.2165/00003495-200565170-00001

M3 - Article

C2 - 16296869

AN - SCOPUS:28144451020

VL - 65

SP - 2429

EP - 2436

JO - Drugs

JF - Drugs

SN - 0012-6667

IS - 17

ER -